Genfit S.A. GNFTF
Set alert
At close · Oct 30
- YTD
- +57.17%
- 1 year
- +153.49%
- Open
- 10.88
- Prev close
- 9.43
- Mkt cap
- 471.79M
- Vol
- 500
- Avg vol
- 84
- EPS
- -2.38
- P/E
- 0.00
More statistics
- Low
- 10.88
- High
- 10.88
News
1 month ago seekingalpha.com
Genfit S.A. (GNFTF) Discusses Developments and Guidance in MASH Diagnostics Transcript
Genfit S.A. (GNFTF) Discusses Developments and Guidance in MASH Diagnostics Transcript
4 months ago globenewswire.com
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily…
4 months ago globenewswire.com
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext:…
4 months ago globenewswire.com
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH
Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and…
-
7 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Tuesday